1.0900
08-十月-24 08:54:58
15 分钟延时
股票
+0.0200
+1.87%
今日范围
1.0700 - 1.1100
ISIN
N/A
来源
NASDAQ
IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine
09 12月 2021 10:05:00 条件 Nasdaq GlobeNewswire
IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial
06 12月 2021 07:00:04 条件 Nasdaq GlobeNewswire
IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
09 11月 2021 10:06:22 条件 Nasdaq GlobeNewswire